Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: MZUBOZ who wrote (699)	12/17/1997 2:47:00 PM
From: Frank Buck	Respond to of 1894

MZUBOZ, Now certainly seems like an excellent time to reacquire. At these levels it appears that you will be in before the institutions. Speaking of price and ownership, check out the room for institutional ownership growth that is yet to develop. ACMI is presently held by only 16 institutions which account for11.2% of the stock. ACMI has a Price to Industry average of only 6.4%. CYTC is presently held by 119 institutions which account for 69.8% of the stock. CYTC has a lofty Price to Industry average of 156.2%. NPTH is currently held by 77 institutions which account for 56.2% of the stock. NPTH has a modest Price to Industry average of 56.6%. NSIX is currently held by 66 institutions which account for 35.1% of the stock. NSIX has a moderate Price to Industry average of 62.4%. With the decent revenues we have been told to expect for the 4th Q'97 coupled with some healthy announcements regarding cost reductions and product acceptance, perhaps some of the institutional ownership will migrate from the competition to AccuMed. Did you own pre or post Alamar/AccuMed merger? Frank